let's start with immunojet.makes drugs that allow chemotherapy agents to directly target a tumor. immun immunogen rise from 11.50 $11.5 about $18. then at the end of october, the stock got pulverized when we learned that immunogen has a less than optimal royalty anment with this drug. even if the drug becomes a block buster, some people feel that immunogen is going to only get a small part of the pie. just today the company presented some data on its small cell lung cancer drug. unlike tdm-1, this one is wholly owned by immunog next. it's only in phase 1 development. final phase 2 data not expected until last year. so could it be big? how big? as the company got a number of cancer drugs that could also be big, including one for ovarian cancer and one for lymphoma, immunogen, the stock has given me a 50% run. let's find out more about how these drugs are progressing and where his company is heading. welcome back to "mad money." >> nice to be here, thank you. >> we are very excited because of the release that you